NCT07134660 Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
| NCT ID | NCT07134660 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Condition | Postoperative Pain, Acute |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2025-09-01 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial evaluates the analgesic effects of liposomal bupivacaine compared to bupivacaine hydrochloride in intercostal nerve block for patients undergoing thoracoscopic lung surgery. Postoperative pain remains a significant issue in thoracic procedures, often leading to complications like pneumonia or delayed recovery. The investigators hypothesize that liposomal bupivacaine, with its extended-release properties, will provide superior pain relief beyond 24 hours compared to standard bupivacaine or no block. Participants will be randomized 1:1:1 to liposomal bupivacaine group , bupivacaine hydrochloride group , or control group . Primary outcome is the area under the curve of pain scores from 25-72 hours post-surgery. Secondary outcomes include opioid consumption, recovery quality (QoR-15), and other complications.
Eligibility Criteria
Inclusion Criteria: * Scheduled for elective unilateral thoracoscopic (VATS) lung surgery * Age 18 to 80 years * American Society of Anesthesiologists (ASA) physical status I-III Exclusion Criteria: * Contraindication to local anesthetics (infection at puncture site, allergy to local anesthetics, coagulopathy or other bleeding risk) * Sensory abnormalities in the planned chest-wall surgical area * Hepatic dysfunction (ALT \> 50 U/L, AST \> 40 U/L, or total bilirubin ≥ 19 μmol/L) or renal dysfunction (serum creatinine \> 112 μmol/L, BUN \> 7.1 mmol/L, or dialysis within 28 days before surgery) * Pregnancy, breastfeeding, women of childbearing potential not using adequate contraception, or planning pregnancy during the study period * Preoperative opioid use, history of chronic pain, or history of opioid abuse * Refusal to provide informed consent
Contact & Investigator
Xin Y Lv, PhD
STUDY DIRECTOR
Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
Frequently Asked Questions
Who can join the NCT07134660 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Postoperative Pain, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07134660 currently recruiting?
Yes, NCT07134660 is actively recruiting participants. Contact the research team at lovewishyou@163.com for enrollment information.
Where is the NCT07134660 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07134660 clinical trial?
NCT07134660 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China. The principal investigator is Xin Y Lv, PhD at Shanghai Pulmonary Hospital, Tongji University, Shanghai, China. The trial plans to enroll 210 participants.